Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
NCT00092274 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL
Last updated 2015-04-21
Summary
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).
Conditions
- Lymphoma, Follicular
Interventions
- DRUG
-
HuMax-CD20
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-09-30
- Primary Completion
- 2005-01-31
- Completion
- 2005-01-31
Countries
- United States
Study Locations
More Related Trials
-
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
NCT01037478 ·Status: COMPLETED ·Phase: PHASE2
-
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
NCT00112723 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
NCT00101244 ·Status: TERMINATED ·Phase: PHASE1
-
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
NCT00359086 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
NCT00920257 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
NCT06930651 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00077194 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
NCT00089284 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00516217 ·Status: COMPLETED ·Phase: PHASE2
-
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
NCT00002501 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT01116154 ·Status: TERMINATED ·Phase: PHASE1
-
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00323934 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
NCT01258998 ·Status: COMPLETED ·Phase: PHASE2
-
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
NCT04156828 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT07283796 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT04849351 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
NCT00695448 ·Status: TERMINATED ·Phase: PHASE1
-
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
NCT00293488 ·Status: COMPLETED ·Phase: PHASE1
-
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
NCT00298467 ·Status: WITHDRAWN ·Phase: PHASE2
-
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
NCT00082888 ·Status: COMPLETED ·Phase: PHASE2
-
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT02420795 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00358982 ·Status: TERMINATED ·Phase: PHASE2
-
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
NCT01200329 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01572519 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
NCT04379167 ·Status: UNKNOWN ·Phase: PHASE2